LobbyingUniversity of Pittsburgh Medical Center lobbying by quarter
University of Pittsburgh Medical Center's latest lobbying report covers Q2 2026, at $350K. The four quarters Q4 2025–Q3 2026 total $1M. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.
University of Pittsburgh Medical Center
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $1M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $370K | 2 |
| Q1 2023 | $370K | 2 |
| Q2 2023 | $380K | 2 |
| Q3 2023 | $370K | 2 |
| Q4 2023 | $380K | 2 |
| Q1 2024 | $380K | 2 |
| Q2 2024 | $330K | 2 |
| Q3 2024 | $340K | 2 |
| Q4 2024 | $330K | 2 |
| Q1 2025 | $330K | 2 |
| Q2 2025 | $330K | 2 |
| Q3 2025 | $330K | 2 |
| Q4 2025 | $330K | 2 |
| Q1 2026 | $340K | 2 |
| Q2 2026 | $350K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$1.4M · 30 reports
- Health issues$1.4M · 30 reports
- Medicare and Medicaid$1.4M · 30 reports
- Insurance$341.5K · 15 reports
- Medical research and clinical labs$257.5K · 4 reports
- Labor, antitrust and workplace$252.5K · 4 reports
- Pharmacy$64K · 4 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES30 reports
- SENATE30 reports
- Centers For Medicare and Medicaid Services (CMS)15 reports
- Natl Institutes of Health (NIH)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseUniversity of Pittsburgh Medical Center | $3.8M | 15 quarters |
| Buchanan Ingersoll & Rooney PC | $1.4M | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| AMANDA LINCOLN | Staff Director, Senate Health, Education, Labor, and Pensions Committee; Legislative Director, Sen. Mike Enzi; Health Policy Director, Sen. Susan Collins | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Buchanan Ingersoll & Rooney PC | $80K |
| 07/17for Q2 | In-house | $270K |
| 04/20for Q1 | Buchanan Ingersoll & Rooney PC | $80K |
| 04/17for Q1 | In-house | $260K |
| 01/20for Q4 2025 | In-house | $250K |
| 01/20for Q4 2025 | Buchanan Ingersoll & Rooney PC | $80K |
| 25/10/17for Q3 2025 | Buchanan Ingersoll & Rooney PC | $80K |
| 25/10/16for Q3 2025 | In-house | $250K |
| 25/10/16for Q3 2025 | In-house | $250K |
| 25/07/22for Q2 2025 | Buchanan Ingersoll & Rooney PC | $80K |
| 25/07/18for Q2 2025 | In-house | $250K |
| 25/04/21for Q1 2025 | Buchanan Ingersoll & Rooney PC | $80K |
| 25/04/11for Q1 2025 | In-house | $250K |
| 25/01/21for Q4 2024 | Buchanan Ingersoll & Rooney PC | $80K |
| 25/01/17for Q4 2024 | In-house | $250K |
| 24/10/21for Q3 2024 | Buchanan Ingersoll & Rooney PC | $80K |
| 24/10/18for Q3 2024 | In-house | $260K |
| 24/07/22for Q2 2024 | Buchanan Ingersoll & Rooney PC | $70K |
| 24/07/18for Q2 2024 | In-house | $260K |
| 24/04/22for Q1 2024 | Buchanan Ingersoll & Rooney PC | $120K |